Painful rejection and other social ills prompt the same opioid response in the brain as physical pain, according to new in vivo PET neuroimaigng of snubbed subjects. 

The Society of Nuclear Medicine and Molecular Imaging has begun accepting abstract submissions for the SNNMI 2014 Annual Meeting, held from June 7-11 in St. Louis.

Sofie Biosciences, an emerging in vivo imaging diagnostics company focused on PET probes, scanners and chemistry systems,announced today that the National Institute of Health has awarded the company a grant under the Small Business Innovation Research (SBIR) program.

At the 55th American Society for Radiation Oncology ASTRO annual meeting, Sept. 22-25 in Atlanta, Royal Philips will feature the latest innovations that address efficient and personalized radiation oncology care for patients and their clinicians.

Siemens’ PETNET Solutions has announced a three-year agreement with The US Oncology Network to supply its entire portfolio of Food and Drug Administration (FDA)-approved PET radiopharmaceutical agents at each of PETNET Solutions’ current Good Manufacturing Practices (cGMP)-certified locations throughout the United States.

Definiens AG, a healthcare company that advances personalized medicine through image analysis and digital pathology solutions, and Advanced Cell Diagnostics (ACD) of Hayward California, a leader in molecular pathology, announced recently the commercial launch of RNAscope® SpotStudio™, a custom-designed image analysis software application for ACD's RNAscope®Assays to detect and quantify RNA biomarkers.

Siemens Healthcare has announced that the FDA has granted 510(k) clearance for Symbia Intevo—the world’s first xSPECT system, which combines the high sensitivity of single-photon emission computed tomography (SPECT) with the high specificity of CT.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2013-2015 SNMMI Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by the late Henry N. Wagner, Jr., MD, and the late Kanji Torizuka, MD, PhD, is designed to provide extensive training and experience in the fields of nuclear medicine and molecular imaging for Japanese physicians in the early stages of their careers.